dc.contributorUniv Queensland
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-11-26T15:29:22Z
dc.date.available2018-11-26T15:29:22Z
dc.date.created2018-11-26T15:29:22Z
dc.date.issued2016-02-01
dc.identifierJournal Of Comparative Pathology. Oxford: Elsevier Sci Ltd, v. 154, n. 2-3, p. 180-185, 2016.
dc.identifier0021-9975
dc.identifierhttp://hdl.handle.net/11449/158833
dc.identifier10.1016/j.jcpa.2016.01.002
dc.identifierWOS:000374920300008
dc.identifierWOS000374920300008.pdf
dc.description.abstractEphrin A3 (EphA3), a member of the ephrin receptor tyrosine kinase family, is involved in a variety of functions in normal cells, especially during embryonic development, and alterations in its expression profile have been observed in several human cancers. However, there are no reports of the expression of EphA3 in normal, hyperplastic or neoplastic canine prostate tissue or in other types of canine tumours. Six normal, 15 hyper plastic and 21 neoplastic canine prostates were examined immunohistochemically with a polyclonal antibody specific for human EphA3. The percentage of positive cells in all prostatic carcinomas was increased, with a mean of 89.28 +/- 5.18% compared with normal (9.17 +/- 6.72%) and hyperplastic prostates (20.00 +/- 8.28%). EphA3 expression was not correlated with the histological subtypes of prostate cancer or with the Gleason score. The increase in EphA3 expression in canine prostatic carcinomas suggests the involvement of this receptor in prostatic carcinogenesis and its potential use as a target for new therapeutic strategies. (C) 2016 Elsevier Ltd. All rights reserved.
dc.languageeng
dc.publisherElsevier B.V.
dc.relationJournal Of Comparative Pathology
dc.relation0,594
dc.rightsAcesso aberto
dc.sourceWeb of Science
dc.subjectcancer
dc.subjectdog
dc.subjectEphA3
dc.subjectprostate
dc.titleOverexpression of Ephrin A3 Receptor in Canine Prostatic Carcinoma
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución